Preventive Effect of Novel Bacterial Polysaccharide and Animal Splenic Protein as Natural Adjuvants on Animal Model of Asthma

Document Type : Original Article


1 Department of Internal Medicine, Medical School of Islamic Azad University- Mashhad Branch, Mashhad, Iran

2 Mohaghagh Hazreati Immunology and Biotechnology Researches Centre, Tehran Iran

3 Department of Immunology, Medical School of Islamic Azad University, Mashhad Branch, Mashhad, Iran

4 Department of Pathology Razavi Hospital, Mashhad, Iran

5 Mashhad University of Medical Science, Mashhad, Iran


Two new adjuvants from natural animal lipids (G2) and bacterial polysaccharide extracts (PC) were previously prepared by our group and showed a reduction in tracheal responsiveness. The aim of this study was to evaluate the preventive effect of recently introduced natural products (G2 and PC) on the development of asthma.
Materials and Methods
Asthma was induced using a standard method in four groups of BALB/c mice. A non-sensitized control group was also included in order to be compared with treated groups. Three groups were premedicated           with novel agents named G2, PC, and a combination of these two for 20 days before starting  the induction of asthma. Bronchoalveolar lavage fluid (BALF) was collected and analyzed for inflammatory cells.  Interferon-γ, and IL-4 and the histopathological of both lungs were also evaluated.
In all pretreated groups, the inflammatory cells infiltration especially eosinophils and smooth muscle hyperplasia decreased significantly. BALF cytology also showed significant decrease in eosinophil              count in all pretreated groups. There was a significant increase in the BALF and serum INF-γ in all pretreated groups but the combination of G2/PC was more effective. BALF IL-4 decreased significantly in                                 the group pretreated with a combination of G2 and G2/PC (4.11±0.86 and 4.02±0.52 pg/ml in G2 and G2/PC, respectively). Serum IL-4 in the PC group was significantly higher than the sensitized control.
G2 and PC may effectively prevent asthma development by activation of the type 1 T helper system.


1. Cohn L, Elias JA, Chupp GL. Asthma: Mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22:789–815.
2. Randolph DA, Stephens R, Carruthers CJ, Chaplin DD. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest 1999; 104:1021–1029.
3. del Giudice MM,  Rocco A, Capristo C. Probiotics in the atopic march: highlights and new insights. Dig Liver Dis 2006; 38:S288-290.
4. Mohaghegh HS, Khanbaba CR, Mazaheri B, Gharagozlo MJ. A novel and invasive metastatic adenocarcinoma of breast cancer (HAZ-1) in small laboratory mice. 14th Iranian congress of Physiology and Pharmacology 1999; p.262.
5. Mohaghegh HS, Nasiri Khalaji S, Mohtarami F, Rahimi A. G2, PC and G2F in allergic asthma. Iran J Pediatr 2004; 13:30-33.
6. Neamati A, Boskabady MH, Afshari JT, Mohaghegh Hazrati S, Rohani A. The effect of natural adjuvants on tracheal responsiveness on cell count in lung lavage of sensitized guinea pigs. Respirology 2009; 14:877-884.
7. Annesi-Maesano I. Asthma epidemiology. Rev Prat  2005; 55:1295-1298.
8.Tarlo SM. Prevention of occupational asthma in Ontario. Can J Physiol Pharmacol 2007; 85:167-172.
9. Arshad SH. Primary prevention of asthma and allergy. J Allergy Clin Immunol 2005; 116:3-14.
10.Devereux G. Early life events in asthma--diet. Pediatr Pulmonol  2007; 42:663-673.
11.Sullivan SD, Melyzer EO. Emerging therapeutic strategies for asthma anagement. J Manag Care Pharm 2003; 9:14-21.
12.Tsitoura DC, Tassios Y. Immunomodulation: the future cure for allergic diseases. Ann N Y Acad Sci  2006; 1088:100-115.
13.Prescott SL, Björkstén DB. Probiotics for the prevention or treatment of allergic diseases. J Allergy Clin Immunol 2007; 120:255-262.
14.Platts-Mills T, Leung DYM, Schatz M. The Role of Allergens in Asthma. Am Fam Physician 2007; 76:675-680.
15.Bloebaum RM, Grant JA, Sur S. Immunomodulation: the future of allergy and asthma treatment. Curr Opin Allergy Clin Immunol  2004; 4:63-67.
16.Sharma S, Jaffe A, Dixon G. Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis. Paediatr Drugs  2007; 9:107-118.
17.Van Rijt LS, Kuipers H, Vos N, Hijdra D, Hoogstenden HC, Lambrecht BN. A rapid flow cytometric method for determining the composition of bronchoalveolar lavage fluid cells of mouse models of asthma. J Immunol Methods 2004; 288:111-121.
18.Yoo J, Tcheurekdjian H, Lynch SV, Cabana M, Boushey HA. Microbial manipulation of immune function for asthma prevention; inferences from clinical trials. Proc Am Thorac Soc  2007; 4:277-282.